The DOI matches its Crossref record.
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group
Abstract
In a randomized multicenter study the influence of hydroxyurea versus busulfan on the duration of the chronic phase and on survival of chronic myelogenous leukemia (CML) was determined. In addition cross resistance and adverse reactions of the drugs were analyzed. From July 1983 to January 1991, 441 CML patients were randomized to receive hydroxyurea or busulfan. Of these, 90.7% were Philadelphia positive; 25.7% were low, 38.2% intermediate, and 36.2% high risk patients according to Sokal's score. The median survival of the busulfan treated Philadelphia-positive patients is 45.4 months and of the hydroxyurea group 58.2 months (P = .008). The survival advantage for the hydroxyurea treated patients is recognized in all risk groups. Sixty four patients reached therapy resistance before blast crisis and were crossed over to the alternative drug. The 23 patients with primary hydroxyurea had a median survival of 5.6 years, the 41 patients with primary busulfan therapy a median survival of 2.7 years (P = .02). Adverse reactions were less frequent with hydroxyurea with no severe adverse effects (lung fibrosis, long lasting bone marrow aplasia). The analysis of white blood cell counts in the course of treatment showed lower counts in the hydroxyurea patients. We conclude that hydroxyurea is superior to busulfan in therapy of CML in chronic phase and should be used as first line therapy. Busulfan may have a role as secondary therapy after hydroxyurea resistance or intolerance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Imatinib Mesylate — A New Oral Targeted Therapy
Savage, D. G., & Antman, K. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmra013339 · Cited by 844
Chronic Myelogenous Leukemia: Biology and Therapy
Faderl, S., Talpaz, M., Estrov, Z., & Kantarjian, H. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00008 · Cited by 462
Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H., Pralle, H., Hossfeld, D., Queisser, W., Loffler, H., Hochhaus, A., & Heinze, B. (1994) · Blood · doi:10.1182/blood.v84.12.4064.bloodjournal84124064 · Cited by 448
Self-citationRibonucleotide reductase and cancer: biological mechanisms and targeted therapies
Aye, Y., Li, M., Long, M. J. C., & Weiss, R. S. (2015) · Oncogene · doi:10.1038/onc.2014.155 · Cited by 436
Systematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease
Lanzkron, S., Strouse, J. J., Wilson, R., Beach, M. C., Haywood, C., Park, H., Witkop, C., Bass, E. B., & Segal, J. B. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-12-200806170-00221 · Cited by 287
Metadata
- Authors
- Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H., Pralle, H., Hossfeld, D., Queisser, W., Loffler, H., Heinze, B., & Georgii, A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1993-07-15
- Volume
- 82
- Issue
- 2
- Pages
- 398-407
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W138942642
- Cited by
- 223
- References
- 0
- FWCI
- 6.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. https://app.cochat.ai/papers/10.1182/blood.v82.2.398.398
- The paper
- Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H., Pralle, H., Hossfeld, D., Queisser, W., Loffler, H., Heinze, B., & Georgii, A. (1993). Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood. https://doi.org/10.1182/blood.v82.2.398.398
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.